ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
1
views
0
references
Top references
cited by
13
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,424
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
End resistance to dolutegravir roll-out
Author(s):
The Lancet HIV
Publication date
Created:
September 2020
Publication date
(Print):
September 2020
Journal:
The Lancet HIV
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
open (via free pdf)
Powered by
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
UCL: UN SDG 01 No Poverty
Author and article information
Journal
Title:
The Lancet HIV
Abbreviated Title:
The Lancet HIV
Publisher:
Elsevier BV
ISSN (Print):
23523018
Publication date Created:
September 2020
Publication date (Print):
September 2020
Volume
: 7
Issue
: 9
Page
: e593
Article
DOI:
10.1016/S2352-3018(20)30231-9
PubMed ID:
32890495
SO-VID:
33d39a4a-7d2c-4889-bd6a-587ebb93054d
Copyright ©
© 2020
License:
https://www.elsevier.com/tdm/userlicense/1.0/
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
2,424
Enhanced Eryptosis Following Exposure to Dolutegravir.
Authors:
Abdulla Al Mamun Bhuyan
,
Elena Signoretto
,
Rosi Bissinger
…
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Authors:
Thokozile R Malaba
,
Irene Nakatudde
,
Kenneth Kintu
…
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Authors:
David Wohl
,
Yazdan Yazdanpanah
,
Axel Baumgarten
…
See all similar
Cited by
13
IMPLEMENTATION AND OUTCOMES OF DOLUTEGRAVIR-BASED FIRST-LINE ANTIRETROVIRAL THERAPY FOR PEOPLE WITH HIV IN SOUTH AFRICA: A RETROSPECTIVE COHORT STUDY
Authors:
Jienchi Dorward
,
Yukteshwar Sookrajh
,
Thokozani Khubone
…
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Authors:
Aditya N Bade
,
JoEllyn McMillan
,
Yutong Liu
…
Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV
Authors:
Yegnasew Takele
,
Tadele Mulaw
,
Emebet Adem
…
See all cited by
Version 1
- Current
Version 1